Introduction
============

The role of animals in the transmission of methicillin-resistant *Staphylococcus aureus* (MRSA), has been extensively documented in the case of the livestock-associated MRSA (LA-MRSA) complex clonal (CC)398 in pigs and people in contact ([@B2]). Whereas pig farming is restricted to specific areas and human communities, companion animals (including cats, dogs, and horses) are geographically wide spread and mostly not related to occupational activities. It has been estimated that 19 millions of cats and dogs live in households in France and that 750,000 equines (horses and ponies) are owned by stud farms or families for horse riding. Deciphering the routes of transmission of MRSA in companion animals is an ongoing issue. Even though all three animal species are in frequent and close contacts with humans, the epidemiology of MRSA is quite divergent, with cats and dogs being frequently colonized or infected by human clones and horses showing a species-specific MRSA distribution.

Several studies showed that MRSA clones circulating in cats and dogs are similar to the ones identified in humans and belong mostly to hospital-acquired clones (HA-MRSA) ([@B22]). This is clinically important since HA-MRSA isolates usually carry more virulence genes \[such as those coding for enterotoxins or the toxic shock syndrome toxin (TSST)\], and also more resistance genes than MRSA originating from animals ([@B27]; [@B3]). The only exception is the *tet*(M) gene, which is highly prevalent in LA-MRSA and MRSA isolates of animal origin but rare in HA-MRSA. This human-related epidemiology suggests that humans may be the source of MRSA isolated in cats and dogs, although those animals may act as a secondary reservoir capable of human re-infections in specific contexts ([@B16]; [@B5]). Reports on MRSA in cats and dogs from England, Germany, Switzerland, and Portugal described the predominance of the sequence type (ST)22 clone, also known as EMRSA-15 or Barnim clone, which is prevalent in human patients in the same countries ([@B31]; [@B12]; [@B16]; [@B37]; [@B7]; [@B42]). The CC398 LA-MRSA has also been sporadically reported in cats and dogs, but always as a minor lineage ([@B15]; [@B37]; [@B42]).

Methicillin-resistant *Staphylococcus aureus* epidemiology in horses presents two distinct time phases. Until the early 2000s, a majority of the reported strains in North America and Europe belonged to the clonal complex (CC)8, with a predominance of the CC8-IV USA500 clone, and clustered into the ST254 and ST8 ([@B39]; [@B26]; [@B10]; [@B38]; [@B32]). Most of these CC8 strains likely originated from humans, and subsequently adapted to horses and disseminated in the equine host, independent to the human epidemiology ([@B41]). After 2004, the emergence and dissemination of a CC398 MRSA clone \[Staphylococcal chromosomal cassette *mec* (SCC*mec*) IV, *spa*-type t011\] has been reported, from potential direct or indirect livestock origin ([@B10]; [@B34]; [@B35]), and this clone is now massively prevalent in horses worldwide. A CC398-IV-t011 MRSA sub-lineage -- named clade C -- has also been described, which most probably encompasses most of the CC398 MRSA that have already been described in hospitalized horses and veterinarians in contact ([@B1]). This clade C is presenting a specific single-nucleotide polymorphism (SNP) consisting in a synonymous substitution in the SNP au309-2. It represents nearly 90% of the MRSA isolated from equine wound infections ([@B37]) in Germany. A recent study shows it present since 2010 in France ([@B13]). An important characteristic of the CC398 isolates is the potential presence of the Immune Evasion Cluster (IEC), composed of combined virulence factors, such as staphylococcal complement inhibitor (*scn*), chemotaxis inhibitory protein (*chp*), staphylokinase (*sak*), and specific staphylococcal enterotoxin genes such as *sea* and *sep* ([@B17]). This bacteriophage-encoded cluster is a marker of re-adaptation to the human host and enhances its human-to-human transmission capacity.

Methicillin-resistant *Staphylococcus aureus* colonizing or infecting companion animals have become of public health concern since transmissions between animals and humans have been documented many times ([@B40]; [@B38]; [@B35]; [@B4]; [@B33]). In France, MRSA clones involved in human infections have been reported in specific studies in cats and dogs ([@B15]) and recently in horses ([@B13]). However, there is still no nationwide comprehensive molecular information on MRSA circulating in cats, dogs, and horses in France, and this was investigated and clarified here over a 5-year period through the French national network for surveillance of resistant bacteria in animals (Resapath^[1](#fn01){ref-type="fn"}^). This study was lined up with the 5-year French action plan EcoAntibio set up by the Ministry of Agriculture, Agri-Food and Forestry^[2](#fn02){ref-type="fn"}^ in 2011. Its first and recently achieved goal was to reduce animal exposure to antibiotics by 25%. The data presented here are of major importance for risk-assessment studies on MRSA transmission in a One-Health perspective.

Materials and Methods {#s1}
=====================

Bacterial Strains
-----------------

From December 2010 to April 2015, antimicrobial susceptibility test (AST) data of all coagulase-positive staphylococci isolated from horses, cats, and dogs (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}) were collected through the Resapath network. The Resapath is a network of 78 veterinary laboratories that are transmitting on a voluntary basis all their AST data as well as the strains of interest to the ANSES (French agency for Food, Environmental and Occupational Health Safety). Only clinical isolates were considered in the frame of this study since the Resapath network does not encompass bacteria colonizing animals. All cefoxitin-intermediate or cefoxitin-resistant isolates, as tested by laboratories member of Resapath using the disk diffusion method (see below), were sent to the ANSES laboratory in Lyon for further characterization. After confirmation of the phenotype by disk diffusion, two PCRs were systematically performed: a triplex PCR targeting the 16S rRNA, *mecA* and *nuc* genes to detect the presence of MRSA ([@B24]), and a simplex PCR using *mecC*-specific primers to detect non-*mecA* MRSA ([@B11]). Species identification was then further assessed using the PCR-RFLP designed by [@B6] to differentiate *S. aureus* from *S. pseudintermedius*, which is the most frequently encountered coagulase-positive *Staphylococcus* in dogs.

Susceptibility Testing
----------------------

Antimicrobial susceptibility test was confirmed by the ANSES laboratory using the disk diffusion method and interpreted according to the guidelines of the Antibiogram Committee of the French Society for Microbiology^[3](#fn03){ref-type="fn"}^. *S. aureus* ATCC 25923 was used as quality control. In addition, 16 antibiotics of veterinary and/or human interest were tested: penicillin G, cefoxitin, cefovecine, kanamycin, gentamicin, tobramycin, tetracycline, erythromycin, spiramycin, lincomycin, chloramphenicol, florfenicol, fusidic acid, enrofloxacin, vancomycin, teicoplanin (Mast Diagnostics, Amiens, France).

Molecular Typing
----------------

The presence of the *mecA*/*mecC* gene was systematically confirmed by PCR ([@B24]; [@B11]). Specific detection of the CC398 by PCR was also systematically performed ([@B29]). This PCR is based on the detection of a specific *sau1*-*hsdS1* gene (responsible for the restriction modification specificity), which is conserved among the CC398 isolates but differs from other MRSA clones. The *spa*-types were determined and assigned as previously described^[4](#fn04){ref-type="fn"}^ ([@B19]).

DNA Microarray
--------------

All *mecA*/*mecC*-positive strains were characterized using microarray-based assay (*S. aureus* Genotyping, Identibac -- Alere) allowing detection of virulence and resistance genes, SCC*mec* types, and assignment to clones and/or MLST clonal complexes. Protocols, target genes for virulence and resistance, databases, typing information, and interpretation management were available at the following internet address: <https://alere-technologies.com/fileadmin/Media/Downloads/op/10620/Manuals/05_16_04_0001_V05_Manual_S.aureus_Genotyping_Kit_2_0.pdf>.

Results
=======

Epidemiological Data and Antibiotic Resistance of MRSA in Cats, Dogs, and Horses
--------------------------------------------------------------------------------

A total of 130 consecutive non-duplicate clinical MRSA isolates were collected from 43 different French districts: 68 isolates from horses, 34 from cats, and 28 from dogs (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). Since 2012, the total number of MRSA collected has significantly decreased in all three animal species (**Figure [1](#F1){ref-type="fig"}**), despite the fact that the total number of coagulase-positive isolates collected (susceptible and resistant to methicillin) followed either a steady or increasing trend.

![Distribution of clones per year in horses **(A)**, cats **(B)**, and dogs **(C)**.](fmicb-08-02493-g001){#F1}

None of the MRSA infected animals presented any epidemiological links since they all originated from different cities, departments or regions, and none of the cats or dogs came from a kennel. MRSA were mostly isolated from skin and soft tissue infections (SSTI) \[horse, *n* = 32 (32/68, 47.1%); dog, *n* = 11 (11/28, 39.3%); cat, *n* = 9 (9/34, 26.5%)\], while MRSA from reproductive tract infections were also highly prevalent in horses (22/68, 32.4%) (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). Isolates globally presented high levels of resistance to several antibiotics, particularly to aminoglycosides (50.0% to gentamicin, 70.0% to kanamycin, 67.7% to tobramycin), tetracyclines (60.0%) and enrofloxacin (48.50%) (**Table [1](#T1){ref-type="table"}**). Major differences were however observed between the CC398 and human-related isolates, with resistances to tetracyclines, phenicols, and aminoglycosides being more prevalent in CC398 isolates, while resistances to macrolides-lincosamides, fusidic acid, and enrofloxacin were more prevalent in human-related isolates (**Table [1](#T1){ref-type="table"}**).

###### 

Resistance to non-beta-lactam antibiotics among MRSA isolated from companion animals.

  Antibiotics       Total of MRSA isolates (*n* = 130)   MRSA isolates belonging to human-related clones^a^ (*n* = 46)   MRSA isolates belonging to CC398 clones (*n* = 64)               
  ----------------- ------------------------------------ --------------------------------------------------------------- ---------------------------------------------------- ------ ---- ------
  Kanamycin         91                                   70.0                                                            27                                                   58.7   52   81.3
  Tobramycin        88                                   67.7                                                            30                                                   65.2   54   84.4
  Gentamicin        65                                   50.0                                                            2                                                    4.3    51   79.7
  Chloramphenicol   27                                   20.8                                                            3                                                    6.5    14   21.9
  Florfenicol       6                                    4.6                                                             0                                                    0.0    6    9.4
  Tetracycline      78                                   60.0                                                            5                                                    10.9   61   95.3
  Erythromycin      43                                   33.1                                                            23                                                   50.0   7    10.9
  Spiramycin        21                                   16.2                                                            14                                                   30.4   7    10.9
  Lincomycin        23                                   17.7                                                            14                                                   30.4   8    12.5
  Fusidic acid      7                                    5.4                                                             5                                                    10.9   0    0.0
  Enrofloxacin      63                                   48.5                                                            41                                                   89.1   21   32.8

a

Strains considered as human-related MRSA clones are listed in Supplementary Table

S2

(underlined strain numbers).

Distribution of MRSA Clones in Horses
-------------------------------------

The most prevalent MRSA clone in horses was the CC398 MRSA clone presenting a SCC*mec* type IV (hereafter named CC398-IV), represented in forty-nine MRSA isolates (49/68, 72.1%) (**Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}** and Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). The *spa*-type t011 was identified in the majority of the isolates (*n* = 42/49, 85.7%), while t899 (*n* = 2), t779 (*n* = 2), t108 (*n* = 1), t1451 (*n* = 1) and one non-typeable isolate were also detected. Conversely to cats and dogs, only two isolates displayed enterotoxin genes \[i.e., *sek*/*seq* (*n* = 1) and *sea* (*n* = 1)\]. The IEC was present in 12.2% (*n* = 6, including 5 type B and 1 type D) of the 49 CC398 isolates. Tetracycline resistance, which has been strongly associated with CC398 strains from livestock so far ([@B28]), was systematically detected and the *tet*(M) gene identified in 48 of the 49 isolates. The *aacA*-*aphD* gene conferring resistance to gentamicin, kanamycin/amikacin, and tobramycin was also frequently identified (46/49, 93.9%) and correlated with phenotypic resistance (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). The other resistance genes were scarce, with the sporadic occurrence of genes conferring resistances to macrolides/lincosamides/streptogramins B \[*erm(A), n* = 3\], streptogramin A \[*vga*(A), *n* = 2\], trimethoprim (*dfrS1, n* = 2), fosfomycin (*fosB, n* = 1), chloramphenicol (*cat, n* = 1), tetracyclines \[*tet*(K), *n* = 2\], or quaternary ammonium compounds (*qacC, n* = 1).

![Schematic representation of all clones associated to horses, cats, and dogs. In the dog section the "unassigned" clones corresponded to strains that could not be assigned to a specific clone by DNA array. These three strains corresponded to CC-*spa* types CC30-t012, CC5-t450, and CC8-t2054 (also see Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). For all strains, associated *spa*-types can be found in Supplementary Table [S2](#SM2){ref-type="supplementary-material"}.](fmicb-08-02493-g002){#F2}

Twelve MRSA (17.6%) isolates clustered with the CC8-IV USA500 clone \[*spa*-type t394 (*n* = 8) and t1952 (*n* = 1)\]. All isolates presented the *seb, sek*, and *seq* enterotoxin genes, and the *tet*(M), *aacA*/*aphD, cat, dfr*(S1), and *fos*(B) resistance genes were detected in all t394 isolates (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). None of them presented the IEC cluster that is classically related to human origin/adaptation.

Among the seven isolates belonging neither to the CC398-IV nor the CC8-IV USA500 clone, three were assigned to the CC8-IV EMRSA-14 (*n* = 2) or to the CC8 Hannover EMRSA (*n* = 1) clones. This CC8 Hannover clone belonged to the ST249-t009 and presented an atypical SCC*mec* element comparable to those described by [@B25]. All three strains presented multiple resistance genes, including to tetracyclines (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). The last four isolates harbored the *mecC* gene and have already been reported in the frame of another study ([@B14]). They belonged to the CC130-XI-t6220, CC130-XI-t1736, CC130-XI-t11050, and CC49-XI-t208 clones (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). These four *mecC*-positive isolates were the only equine isolates that were not resistant to tetracyclines and presented no other resistance genes.

Distribution of MRSA Clones in Cats
-----------------------------------

Most isolates belong to the prototypic CC8-IV Lyon clone (13/34, 38.2%) or its *sea*-negative variant (*n* = 1). The majority have *spa*-type t008 (*n* = 8) (**Figure [1](#F1){ref-type="fig"}** and Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). In addition to these 14 isolates, another 10 isolates belong to human-related clones: CC5-IV Pediatric (*n* = 3) and New Pediatric (*n* = 2) clones, CC5-II (*n* = 3), CC22-IV Barnim (*n* = 1), CC5-I Geraldine (*n* = 1) clones. Among the latter, the IEC (marker of human adaptation) was detected in a vast majority of the isolates (*n* = 17; 17/24, 70.8%). The IEC type A (*sea, sak, scn, chp*) was identified in one isolate, the IEC type B (lacking *sea*) in four isolates, and the IEC type D (lacking *chp*) in 12/13 isolates from the Lyon clone ([@B36]). Among the human-related clones, only one isolate was resistant to tetracyclines without *tet*(M) gene.

On the contrary, the *tet*(M) gene was present in all nine isolates belonging to the CC398 MRSA clone, among which 6 harbored SCC*mec* type IV (CC398-IV; including four isolates with *spa* type t011) and three of the SCC*mec* type V (CC398-V). The IEC cluster was only found in three isolates \[type B (*n* = 1) or type D (*n* = 2)\]. All CC398-V clones presented at least the *tet*(M) and *fexA* resistance genes, whereas the CC398-IV clone carried the *tet*(M) and *aacA*-*aphD* genes. The co-occurrence of the *tet*(M) and *tet*(K) genes was identified in two *spa*-type t034 CC398-V. This association, recently shown to increase the fitness of CC398-V strains in the presence of tetracyclines ([@B20]), was also identified here in a t1451 CC398-IV isolate originating from a horse (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). Finally, one isolate, belonging to the CC130-XI t843 clone, harbored the *mecC* gene with no associated resistance or enterotoxin genes.

Distribution of MRSA Clones in Dogs
-----------------------------------

As for cats, nine isolates belonged to the CC8-IV Lyon clone (32.1%) or to other sporadically occurring human-related clones (*n* = 10) (**Figure [1](#F1){ref-type="fig"}** and Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). A total of 16 out of the 28 isolates displayed the IEC cluster \[type B, *n* = 6; type D, *n* = 10 (including the nine Lyon clone isolates)\]. Only one isolate did not present any associated enterotoxin gene. Resistance phenotypes to macrolides (10/28, 35.7%), aminoglycosides (15/28, 53.6%), and fosfomycin (18/28, 64.3%) were frequently encountered, whereas only one isolate was resistant to tetracyclines in the absence of the *tet*(M) gene. The CC398-IV clone was identified in six tetracycline-resistant isolates (21.4%), among which two presented the IEC cluster (type B and type D). The last three isolates belonged to the CC-*spa* types CC30-t012, CC5-t450, and CC8-t2054 but could not be assigned to any specific clone by the DNA array. Finally, no *mecC* gene was detected in dogs.

Discussion
==========

This study describes the largest collection of MRSA isolates ever collected in France from companion animals (horses, cats, and dogs). It can be compared with the MRSA collection from these three animal species published by [@B37] in Germany, and also to the data very recently published in a specific study focused on MRSA in horses by [@B13] in France.

In our study, only one MRSA was isolated from horses in 2010, likely due to a poor representation of horses, cats and dogs in the Resapath network at the time (the total number of coagulase-positive staphylococci reported in 2010 was respectively 5 in horses, 11 in cats, 88 in dogs). Since 2011, this gap has been progressively filled in and the obvious decrease in the total number of MRSA collected over years (**Figure [1](#F1){ref-type="fig"}**) likely reflects a true decrease in the prevalence of MRSA in horses, cats, and dogs in France. A major reason for this decrease may well be the recent global reduction in the use of antibiotics in the veterinary field in France, in line with the 5-year national action plan EcoAntibio of the Ministry of Agriculture, Agri-Food and Forestry. Indeed, a decrease (from 19.4% to 28.1%) was observed in the global exposure to antibiotics of respectively cats/dogs and horses^[5](#fn05){ref-type="fn"}^. Such a valuable trend will be thoroughly monitored in the near future.

Success in Horses of the CC398-IV MRSA Clone Belonging to the *spa*-Type t011
-----------------------------------------------------------------------------

The molecular characterization of the horse collected isolates highlights that MRSA identified in these animals are independent to the human MRSA epidemiology. Two major animal-associated clones were identified in France: the CC8-IV USA500 and the CC398-IV-t011 clones. The CC8-IV USA500, which is the predominant clone infecting horses in North America, also recently described as an environmental contaminant in an equine veterinary center ([@B39]; [@B32]), was detected in France between 2011 and 2013, with a last occurrence in early 2014. This suggests that this clone, uncommon in the human population in France and worldwide, is prone to colonize and/or infect horses worldwide. Yet CC8-IV USA500 seems to have been totally replaced by the horse-specific CC398-IV belonging to the *spa*-type t011 in France (**Figure [1](#F1){ref-type="fig"}**), confirming its international spread and high fitness/adaptation to horses. Between 2013 and 2015, only 7/39 (17.9%) isolates did not belong to the CC398 clone. Of note, four out of these seven isolates displayed the *mecC* gene. Whether horses may be prone to disseminate *mecC* genes or not remains questionable. Both in terms of management by veterinarians and with regards to the global burden antimicrobial resistance, the replacement of CC8-IV USA500 by the CC398-IV-t011 clone may be considered good news since CC398 were co-resistant to aminoglycosides and tetracyclines only, whereas USA500 additionally displayed resistances to macrolides-lincosamides, chloramphenicol, sulfonamides, and fosfomycin. Even though these antibiotic molecules are not all licensed for horse treating, any decrease in antibiotic resistance burden is to be noticed since it may also decrease the risk of co-selection of resistant isolates in other animal species or in humans. This is of course only on a resistance perspective, and the differences in virulence capacities (such as biofilm formation or the presence of adhesion factors) will also have to be considered.

Considering the nosocomial and zoonotic potential of MRSA isolated from horses, equine veterinarians should pay specific attention to both antibiotic treatments and hygiene measures, to limit MRSA selection and transmission. The rate of MRSA carriage in healthy horses, as well as the potential human-to-animal or animal-to-human transmission in both veterinary clinics and in equestrian centers was studied on certain occasions and certainly deserve further investigation ([@B35]; [@B9]; [@B18]).

Human-Related MRSA Clones in Cats and Dogs
------------------------------------------

Our data also underline that MRSA isolated from cats and dogs mirror the epidemiology of hospital-acquired human MRSA ([@B22]). The CC8-IV Lyon clone was the most frequently identified MRSA clone in both animal species, followed by the occurrence of numerous sporadic lineages. This is in accordance with a similar study previously conducted in France on a smaller number of isolates ([@B15]). The ST22 Barnim clone is again rare in France despite its high prevalence in animals in surrounding countries ([@B31]; [@B12]; [@B16]; [@B37]; [@B7]; [@B42]). Its rare occurrence is most likely related to its low prevalence in French hospitals and in the community. The CC398 clone was detected in 21.4% of all dogs' and 26.5% of all cats' isolates, which is more frequent that what has been reported in Germany and much more than what has been recently observed in France (2/23, 8.7%) or in other European countries ([@B15]; [@B37]; [@B42]). Since no links could be inferred between animals sampled and pig farming or contact with livestock, the hypothesis of a progressive replacement of existing human MRSA clones in cats and dogs by the CC398 cannot be excluded, as observed in horses,. Data collected are too limited to confirm such an hypothesis and this will deserve to be followed-up, yet CC398 clones disseminated among humans have recently been exemplified in Denmark, not all to be attributed to contact with livestock ([@B21]). Interestingly, all CC398 isolates presented the *tet*(M) gene, whereas all non-CC398 were devoid of the gene. Other *tet* genes being rare (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}), tetracycline susceptibility in MRSA from cats and dogs may be used as a marker for human-related isolates, mirroring the fact that tetracycline-resistance \[or the *tet*(M) presence\] can be used as a marker for MRSA CC398 in humans living in high pig-farming areas ([@B23]).

Conclusion
==========

We show here a divergent epidemiology between cats/dogs and horses, with the first two species being largely colonized by human-related isolates mirroring the human MRSA epidemiology. These strains produce enterotoxins more frequently and display a higher prevalence of the IEC cluster than the animal-associated MRSA isolates colonizing horses. Considering the proximity of humans with their pets and the possibility of human re-infection, prevalence of MRSA in cats and dogs is undoubtedly a public health issue that deserves to be monitored. Conversely, horses are mostly infected by animal-associated isolates that differ from the traditional ST398 LA-MRSA with the particular prevalence of the CC398-IV MRSA clone belonging to the *spa*-type t011. Cats and dogs are also infected by CC398 MRSA clones, and special attention will have to be paid to the IEC-positive CC398 MRSA isolates, whose prevalence was substantial in our study (11/64, 17.2%). This rate is particularly high compared to the one detected in LA-MRSA from in MRSA from horses in Germany (∼10%) ([@B8]). Of note, no IEC-positive CC398 MRSA had been detected from pigs' isolates in the same study. Re-adaptation to a human host, due to closer contacts between companion animals and humans compared to pigs and farmers, may favor virulence and animal-independent dissemination of such MRSA isolates in humans ([@B30]). Taken together, this set of data promote a regular surveillance of MRSA in companion animals in the coming years to assess whether the CC398 would replace human-related MRSA clones in cats and dogs and whether those clones will be able to re-adapt to the human host.
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